ILLUMINA VENTURES

Revolutionizing bacterial diagnosis to fight antibiotic resistance

October 2020 - “Pattern’s next-gen clinical microbiology platform will set new standards in antibiotic susceptibility testing,” said Nick Naclerio, Ph.D., Founding Partner at Illumina Ventures. “By measuring phenotypic bacterial response at single-cell resolution, Pattern is meeting the challenge of antibiotic resistance with an innovative platform that is poised to revolutionize bacterial diagnosis.”